Abstracts tagged "osteoarthritis and x-ray"

Abstract Number: 1L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Marc C. Hochberg¹, Ali Guermazi², Hans Guehring³, Aida Aydemir⁴, Stephen Wax⁵, Patricia Fleuranceau-Morel⁴, Asger Reinstrup Bihlet⁶, Inger Byrjalsen⁶, Jeppe Ragnar Andersen⁶ and Felix Eckstein⁷, ¹University of Maryland School of Medicine, Baltimore, MD, ²Boston Imaging Core Lab, LLC, and Boston University School of Medicine, Boston, MA, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Institute of Anatomy, Paracelsus Medical University, Salzburg, Austria

Background/Purpose: Sprifermin, a novel recombinant human fibroblast growth factor-18 is currently investigated as a potential disease-modifying osteoarthritis (OA) drug. Two-year primary data from a 5-year…
Abstract Number: 1207 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Structural Measures in Knee Osteoarthritis: Baseline Values and Change from Baseline Discriminate Patients Subsequently Receiving Knee Replacement
C. Kent Kwoh¹, Hans Guehring², Michael J Hannon³ and Aida Aydemir⁴, ¹University of Arizona Arthritis Center, Tuscan, AZ, ²Merck KGaA, Darmstadt, Germany, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Structural measures of knee OA (KOA) progression include assessment of radiographic joint space width (JSW) and quantitative MRI (qMRI) measurement of cartilage thickness, both…
Abstract Number: 202 • 2014 ACR/ARHP Annual Meeting
Is Schuss View Alone Enough for the Diagnosis of Femorotibial Osteoarthritis ? the Khoala Cohort Study
Christian Roux¹, Bernard Mazieres², Evelyne Verrouil², Anne-Christine Rat,³, Patrice Fardellone⁴, Bruno Fautrel⁵, Jacques Pouchot⁶, Alain Saraux⁷, Francis Guillemin⁸, Liana Euller Ziegler⁹ and Joel Coste¹⁰, ¹Rhumatologie, Hopital Archet 1 - Université Nice Sophia Antipolis, Nice, France, ²CHU Toulouse, Toulouse, France, ³Université de Lorraine, Université Paris Descartes, Apemac, EA 4360, Nancy, France, ⁴Service de Rhumatologie, Hôpital Nord, C.H.U. d'Amiens, Amiens, France, ⁵CHU - Hôpital Pitié-Salpêtrière, Paris, France, ⁶Medecine Interne, Hopital Louis Mourier, Colombes, FRANCE, France, ⁷Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, ⁸INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ⁹151 rte de St Antoine de Gines, CHU de Nice -Université Nice Sophia Antipolis, Nice, France, ¹⁰CHU Hotel Dieu, Paris, France
Background/Purpose: Associating an anteroposterior (AP) extended-knee X-ray with a semiflexed AP or posteroanterior (PA) view is considered the gold standard for radiologically diagnosing tibiofemoral osteoarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].